Patent: Combining Sansrosa and Finacea

Galderma is staking out its claim on potential rosacea topicals with another patent being published. This patent details potential topicals that are combinations of the active ingredients in Sansrosa and Finacea, namely Brimonidine Tartrate and Azelaic Acid.

The touted benefits from combining the two actives is a reduction in rebound redness and a greater tolerance for the actives themselves.

[0013] Surprisingly, the applicant has observed that a combination of azelaic acid with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family allows a more effective treatment of rosacea, with fewer side effects irrespective of the duration of application of this combination. In particular, such a combination makes it possible to substantially reduce the duration of treatment and to obtain a greater reduction in the symptoms of rosacea. This combination may also make it possible to eliminate the rebound effect normally observed at the end of treatment with alpha-1 or alpha-2 adrenergic receptor agonists.

The patent application is broad, referring to many possible combinations of

  • alpha-1 adrenergic receptor agonist family – metaraminol bitartrate, midodrine, methoxamine, mephentermine, phenylephrine, oxymetazoline, tetrahydrozoline, naphazoline or xylometazoline and
  • alpha-2 adrenergic receptor agonist family – apraclonidine, brimonidine, clonidine, mirtazapine, dexmedetomidine, guanbenz acetate, lidamidine, lofexidine, methyldopa, rilmenidine, talipexole, tiamenidine, tizanidine, tolonidine.

The preferred composition according to the invention comprises brimonidine and azelaic acid.

Patent Application

Agent: Galderma Research & Development Snc – Biot, FR

USPTO Application #: 20130190317

Filed: August 5, 2011

July 25, 2013

Combination of compounds for treating or preventing skin diseases

Abstract: The invention relates to a combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea.

It is the combination of a compound selected from azelaic acid and salts thereof with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family.

The invention also relates to a product in the form of a kit containing:

(a) a first composition comprising a compound selected from azelaic acid and salts thereof, and

(b) a second composition different from the first one and comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family, as a combination product for application thereof as a medicament for treating and/or preventing skin diseases and in particular rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

2 Reader Comments

  1. George says:

    Is this essentially not them stating that sansrosa does actually cause rebound redness?

    • David Pascoe says:

      At the level of a patent application yes it does sort of suggest that. All sorts of claims are made in patents though – some to make it look like an invention others to cover your competition from coming close to your property. I don’t think it doesn’t mean too much as far as a new admission from Galderma is concerned though as there is published adverse event data.

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.